Intravenous Infusions PLC will inject GH¢50 million in equity to revitalize operations after a turbulent year, its board chair Isaac Osei announced at the company’s annual meeting.
The move aims to plug critical funding gaps and ease supply chain bottlenecks that delayed raw material imports, slashing 2024 revenue by 20.6%.
Osei acknowledged the crunch: “Debt servicing pressures and supply snarls choked production, despite our products remaining Ghana’s preferred brand.” The net pre-tax loss hit GH¢480,000, worsened by GH¢1.98 million in exchange losses. Staff are now mobilizing to reverse the slide, targeting domestic and international growth.
Managing Director Moukhtar Soalihu confirmed aggressive regional plans. “We’re unwavering in expanding to Ivory Coast, Liberia, and Sierra Leone,” he stated. The capital will also fund retail segment entry and stakeholder collaborations to strengthen branding.
For shareholders, the pledge signals a turnaround bid. Yet challenges linger: timely material sourcing and regional execution risks loom. Can this cash infusion cure the company’s ailments? Leadership insists yes—betting on staff grit and West Africa’s demand.
